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Abstract Considerable non-allelic heterogeneity for
autosomal recessively inherited Charcot-Marie-Tooth
(ARCMT) disease has challenged molecular testing and
often requires a large amount of work in terms of DNA
sequencing and data interpretation or remains unpractical.
This study tested the value of SNP array-based whole-
genome homozygosity mapping as a first step in the
molecular genetic diagnosis of sporadic or ARCMT in
patients from inbred families or outbred populations with
the ancestors originating from the same geographic area.
Using 10 K 2.0 and 250 K Nsp Affymetrix SNP arrays, 15
(63%) of 24 CMT patients received an accurate genetic
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diagnosis. We used our Java-based script eHoPASA
CMT—easy Homozygosity Profiling of SNP arrays for
CMT patients to display the location of homozygous
regions and their extent of marker count and base-pairs
throughout the whole genome. CMT4C was the most
common genetic subtype with mutations detected in
SH3TC2, one (p.E632Kfs13X) appearing to be a novel
founder mutation. A sporadic patient with severe CMT was
homozygous for the c.250G [ C (p.G84R) HSPB1 muta-
tion which has previously been reported to cause autosomal
dominant dHMN. Two distantly related CMT1 patients
with early disease onset were found to carry a novel
homozygous mutation in MFN2 (p.N131S). We conclude
that SNP array-based homozygosity mapping is a fast,
powerful, and economic tool to guide molecular genetic
testing in ARCMT and in selected sporadic CMT patients.
Keywords Autosomal recessive CMT  Homozygosity
mapping  SNP array  Hereditary neuropathies  Gene
Introduction
Charcot-Marie-Tooth (CMT) disease is a common group of
inherited neuropathies with autosomal dominant (AD-
CMT), autosomal recessive (ARCMT) or X-linked inheri-
tance. It has been shown that ARCMT, also known as CMT
type 4 (CMT4), is genetically heterogeneous with at least
14 genes identified so far [1] (Supplementary Table 1).
CMT4 is usually characterized by an early disease onset
and a more severe course of the disease compared to
ADCMT [2, 3]. The underlying pathology of the peripheral
nerves has been shown to be due to demyelinating or
axonal nerve damage or a combination of both [1]. How-
ever, the resulting phenotypes are generally very similar
making it often impossible to distinguish the different
genetic subtypes on clinical and electrophysiological
grounds. Given the large number of genes involved in the
pathogenesis of CMT and that all Mendelian modes of
inheritance might apply in a sporadic case, molecular
testing often requires a considerable effort in terms of cost
and time, thus becoming a challenge for clinicians and
human geneticists.
Recent molecular genetic studies have shown consid-
erable progress in the identification of recessive disease-
causing genes using positional cloning by homozygosity
(equal autozygosity) mapping that tests the assumption that
a homozygous mutation in a recessive disease is identical
by descent (IBD) by segregating twice to the affected
person from a common ancestor through both the maternal
and paternal line [4, 5]. The value of single nucleotide
polymorphism (SNP) array-based homozygosty mapping
in the identification of a recessive disease gene for both
inbred and outbred populations has been demonstrated [4,
6]. We here show that whole genome SNP homozygosity
mapping and subsequent DNA sequencing of a known
candidate gene provide a fast, cost-effective, and powerful
approach to identify the disease locus in autosomal reces-
sive and in selected sporadic CMT patients and can guide
molecular genetic testing.
Materials and methods
Patients
The present study included a total of 24 unrelated index
probands with sporadic or ARCMT neuropathy who had
received a detailed neurological and neurophysiological
examination. The study was performed with written
informed consent and was approved by the local Ethical
Committee of the Medical University of Graz, Austria.
Based on the family history the patients were subdivided
into three groups:
Group 1 (G1)
Includes 6 probands (G1-1 to G1-6) diagnosed as CMT4
whose parents are first cousins.
Group 2 (G2)
Includes 11 probands (G2-7 to G2-17) with sporadic or
ARCMT whoes ancestors originate from the same or a near
geographical area making distant relationship of the par-
ents possible.
Group 3 (G3 control group)
Includes 7 patients (G3-18 to G3-24) with genetically
confirmed CMT or related neuropathies caused by homo-
zygous mutations [7, 8]. In these individuals SNP homo-
zygosity mapping was carried out to retrospectively test for
homozygous areas. For G3-18 to G3-21 consanguinity of
the parents was known. Group 3 also includes a patient
with a mutation in the HSN2 gene which has been pub-
lished previously [8].
SNP array genotyping and identification
of homozygous regions
In order to define the molecular genetic basis of the disease
in the CMT patients, a search for regions of putative
homozygosity-by-descent was initiated by conducting a
whole genome scan using Affymetrix SNP arrays. Geno-
mic DNA samples from all patients of group 1 and group 3
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(G1-1–6; G3-18–24), from G2-7–10, G2-13, G2-15, G2-
17, and from a healthy control were hybridized to Gene-
Chip Human Mapping 10 K 2.0 SNP arrays (Affymetrix,
Santa Clara, CA, USA) using the protocols recommended
by the manufacturer. Samples from patients G1-1–4, G2-
7–14, G2-16, G3-18, G3-23, G3-24, and from a healthy
control were also hybridized to GeneChip Human Map-
ping 250 K Nsp SNP arrays subsequently. Genotypes of
both array types were called using GeneChip Genotyping
Analysis Software (Version 4.0) and default thresholds.
The overall call rate of each array succeeded 95%.
Both the 10 K 2.0 and the 250 K Nsp SNP results of
each patient were further analyzed by using our self-
developed Java-based tool (eHoPASA-CMT—Easy
Homozygosity Profiling of Affymetrix SNP arrays for
CMT patients) which had been designed to quickly extract
genome wide regions of homozygosity (‘‘homozygosity
plotting’’) that may harbor the disease gene without any
linkage computations [9]. The software accepts tab-
delimited SNP array genotype data and generates result
files for scaled homozygosity profile display. Single
occurrences of genotyping failures or undetermined geno-
types (‘‘no calls’’) are being ignored, when at least seven
neighboring genotypes on each side are homozygous [10].
For the homozygosity regions plotting we arbitrarily
defined a homozygous region on the occurrence of at least
eight or more consecutive homozygous SNPs (hSNPs,
10 K 2.0 array) and 20 hSNPs (250 K Nsp array) by the
user-selectable parameter in the program. Homozygosity
profiles along the entire human genome were plotted using
the R statistical software package [11]. In addition to other
software programs [10] our tool was adapted to quickly
inspect and visualize homozygosity profiles at the ARCMT
loci. In the next step the resulted homozygosity profiles
were further mapped against ARCMT loci using only
homozygosity regions with at least 15 consecutive homo-
zygous SNPs (hSNPs, 10 K 2.0 array) and 40 hSNPs
(250 K Nsp array) to discover the regions of homozygosity
within these loci. Subsequently only CMT genes located
within these regions were sequenced (Supplementary
Table 2). All analyses are based on human reference
sequence hg18 (NCBI Build 36 Version 1) genome
assembly annotations. The eHoPASA-CMT software itself
and R programming code for plotting of the homozygosity
profiles are freely available for download (http://ehopasa.
sourceforge.net).
Mutation analysis
All exons and exon–intron boundaries of ganglioside-
induced differentiation-associated protein 1 (GDAP1), SH3
domain and tetratricopeptide repeats 2 (SH3TC2), heat
shock 27 kDa protein 1 (HSPB1), early growth response 2
(EGR2), neurofilament protein, light chain (NEFL), lamin
A/C (LMNA) and mitofusin 2 (MFN2) were screened for
mutations by direct sequencing (ABI 3730 Genetic Ana-
lyzer, Applied Biosystems, Foster City, CA, USA) fol-
lowing standard methods. Frataxin (FXN) was analyzed
using standard methods [12].
Results
Patients
Detailed clinical and neurophysiological findings in the 24
CMT patients (6 females, 18 males) aged 7–59 years
(mean 24 years) with disease onset ranging from birth to
25 years (mean 7 years) are shown in Supplementary
Table 3. In ten patients the phenotype was complicated and
included additional proximal weakness, deafness, mild
retardation, ataxia, nephropathy, hyperhydrosis, and hy-
perextensible skin. NCS of the median or ulnar motor nerve
were known in 21 of 24 probands and confirmed the
presence of a demyelinating (14), axonal (4) or interme-
diate neuropathy (3) in the patients.
Homozygosity plotting identifies the individual
ARCMT locus in the majority of cases
Low- and high-density (10 and 250 K) array-based
homozygosity plotting revealed up to four regions of ho-
moyzgosity at ARCMT loci, with a higher number and
larger extent of homozygosity in individuals from group 1
as compared to individuals from group 2 and the control
group (group 3); see Supplementary Table 2. As expected,
high-density arrays revealed a higher resolution of homo-
zygosity across the genome at ARCMT loci. Using our
criteria to define a homozygous region disease-causing
mutations at homozygous ARCMT loci were subsequently
identified in 5/6 patients from group 1, in 4/11 patients
from group 2, and 6 of 7 patients from group 3 (Supple-
mentary Table 2).
Mutations in the SH3TC2 gene
In three Turkish CMT1 patients (G1-3, G1-4 and G3-18)
without known relationship, we identified a novel mutation
(c.1894_1897 delGAGGinsAAA) in the SH3TC2 gene
(Fig. 1a). Patients G1-3 and G1-4 were homozygous at the
SH3TC2 locus but haplotypes obtained from the 10 K 2.0
SNP array were different. In individual G3-19 homozy-
gosity at this locus was even absent when using the 10 K
2.0 SNP array. However, using 250 K Nsp arrays revealed
a 2.5 Mb interval in all three patients including 284 iden-
tical hSNPs suggesting a common haplotype. Patient G2-8
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and G2-15 from Austria with severe early onset CMT1
demonstrated significant homozygosity at the SH3TC2
locus (Supplementary Table 2) which guided initial genetic
testing of the SH3TC2 gene. Both patients carried the
known c.2860 C [ T (p.R954X) mutation in a homozy-
gous state. In the Turkish patient G2-17 with early onset
CMT1 and scoliosis homozygosity at the SH3TC2 locus
also suggested subsequent screening of the SH3TC2 gene
that revealed the c.1285 G [ T (p.E429X) mutation.
Mutations in the HSPB1 gene
Patient G2-7, whose parents originated from the same
geographic area, was found to be homozygous at the
HSPB1 locus (Supplementary Table 2, Fig. 2a). This pro-
band exhibited an early onset severe CMT phenotype.
Median NCS were reduced to 35 m/s. Sensory symptoms
were not reported and sensory NCS were within the normal
range. There was no family history except for prominent
foot deformity in the paternal grandfather. Direct
sequencing of HSPB1 detected a homozygous mutation
(c.250G [ C; p.G84R; Fig. 1b) which has previously been
reported to segregate with autosomal dominant CMT [13].
Subsequent examination of the patient’s father revealed
absent achilles tendon reflexes and reduced patellar and
upper limb tendon reflexes. Muscle strength and tone were
normal and vibration sense was preserved including
vibration at the hallux. Motor and sensory NCS were in the
normal range in upper and lower limbs. The mother did not
complain of any symptoms and neurological examination
was normal except for reduced achilles tendon reflexes.
However, motor NCS were severely slowed and reduced in
amplitudes in the lower limbs (left tibial nerve: 27 m/s;
1.5 mV; right tibial nerve: 31 m/s, 1.4 mV). NCS of the
sural nerve revealed reduced amplitudes and mild con-
duction slowing (left side: 7 lV; 40 m/s; right side:
8.9 lV; 41 m/s). NCS in the upper limbs were in the
normal range except for mild slowing of distal motor
latencies in the absence of clinical signs of a carpal tunnel
syndrome. Both parents were heterozygous for the HSPB1
c.250G [ C; p.G84R mutation.
Mutations in the MFN2 gene
Patient G1-2 with severe and typical early onset CMT1 was
initially excluded for mutations in the common CMT1
genes (PMP22, MPZ, GJB1, LITAF, GDAP1). Subsequent
analysis of the 250 K Nsp SNP array revealed significant
homozygosity at the PLEKHG5/MFN2 locus (Supple-
mentary Table 2, Fig. 3a). While mutations in PLEKHG5
were excluded initially, we identified the c.392A [ G,
(p.N131S) mutation in MFN2. This mutation is not listed in
databases (Ensemble, NCBI, CMT mutation database) and
Fig. 1 Detection of ARCMT mutations. a Partial sequence chro-
matogrom displaying SH3TC2 mutations c.1894_1897 del-
GAGGinsAAA (p.E632Kfs13X, exon 11, arrow) identified in three
patients. b Homozygous HSPB1 c.250G [ C (p.G84R, exon 1)
mutation (arrow). c Homozygous MFN2 c.392A [ G, p.N131S (exon
3) mutation (arrow)
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has not been reported in the 1,000 genomes project
(http://www.1000genomes.org). The parents of this patient
were first cousins and were normal on clinical and elec-
ropyhsiological examination (Fig. 2b). The same homo-
zygous mutation was confirmed in a distantly related
individual exhibiting the same phenotype. Comparing
homozygosity profiles of both patients revealed only one
overlapping homozygous area at the MFN2 locus on
chromosome 1 (Figs. 3a, 1c).
Mutations in the GDAP1 gene
Patient G1-5 with axonal early onset CMT showed an
extended homozygous area of 112 hSNPs using the 10 K
2.0 array along the GDAP1 locus (Supplementary Table 2,
Fig. 3b) and direct sequencing of GDAP1 revealed the
known homozygous c.482G [ A, (p.R161H) mutation.
The two further GDAP1 mutations (c.174_176del3ins-
TGTG, p.Leu58LeufsX4, and c.458 C [ T, p.P153L) have
been published previously [7].
Mutations in the FXN gene
Patient G1-6 who had been previously diagnosed with
CMT2 showed no homozygosity at any CMT locus.
However, because mild retardation and mild ataxia were
known in this patient we also looked for homozygous
regions at the AR ataxia loci and identified a convincing
area of 71 hSNPs at the FXN locus using the 10 K 2.0
array. We thus tested for Friedreich ataxia and detected a
biallelic trinucleotide repeat expansion.
Mutations in the NDRG1, PRX and HSN2 gene
Patient G3-22 and G3-23 with severe CMT 1 and partial
hearing loss had no history of parental consanguinity. Both
patients who were already known to carry the NDRG1
founder mutation (c.442 C [ T, p.R148X) [14], showed
convincing homozygous areas at the NDRG1 locus (Sup-
plementary Table 2) when using the 250 K Nsp Array. The
homozygous PRX mutation (c.2098 delG, p.A700PfsX17)
and the HSN2 mutation (c.550 C [ T, p.Q184X) have been
published previously [7, 8]. Also, at these loci the probands
were homozygous at the corresponding loci (Supplemen-
tary Table 2).
Discussion
The identification of at least 14 genes involved in the
pathogenesis of ARCMT has challenged successful
molecular genetic testing. In our series of 24 index patients
Fig. 2 Pedigree. a Pedigree of the family of patient G2-7 (III/1)
carrying the HSPB1 mutation c.250G [ C, p.G84R. * This individual
was reported having had prominent pes cavus. ** Clinically normal,
but severe slowing of NCV in the LL. *** Clinically normal, but
reduced tendon reflexes. b Pedigree of the family of patient G1-2 (V/
1) carrying the MFN2 mutation c.392A [ G, p.N131S
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with sporadic or ARCMT disease, 15 (63%) received an
accurate genetic diagnosis by application of SNP array-
based whole-genome homozygosity plotting used as the
first step of the genetic analysis. Our newly-developed
software programe considering the physical positions of the
known ARCMT loci enables fast and simple inspection of
homozygosity at ARCMT loci, and displays in detail the
extent of homozygosity throughout the genome.
Because our patients originated from consanguineous
families or their ancestors came from the same geographic
area, homozygosity for a disease-causing mutation IBD
was likely or possible. In the majority of all probands born
to consanguineous parents or in those who were already
known to carry rare homozygous mutations, comparison of
the low-density (10 K 2.0) array and the high-density
250 K Nsp array data showed that the 10 K 2.0 SNP array
was sufficient to pinpoint the ARCMT locus harboring the
mutation. However, in patients of groups 2 and 3 with
possible distant parental relationship application of the
10 K 2.0 SNP array enabled a genetic diagnosis in only 4
of 15 patients, whereas 3 further patients were diagnosed
following 250 K Nsp array data analysis. Proband G1-1
showed homozygosity at the NEFL locus only but muta-
tions in this gene could be excluded by direct sequencing
suggesting that another dominant or a hitherto unknown
ARCMT gene might be responsible for the disease. Also,
smaller deletions or duplications in NEFL cannot be ruled
out definitely as has been shown previously [15, 16]. Based
on data obtained here we conclude, that homozygous
mutations known ARCMT genes can be excluded with
high probability in patients who do not show extended
homozygosity at known loci. Moreover, using SNP array
analysis may also be straightforward in the detection of
large homozygous deletions. Patient G1-6, finally diag-
nosed with Friedreich ataxia, highlights the value of SNP-
array based whole-genome homozygosity mapping in the
differential diagnosis of ARCMT.
Our data obtained in patients from groups 2 and 3 are
consistent with the findings of recent studies demonstrating
that high-density SNP array-based homozygosity mapping
can successfully be applied to non-consanguineous single
individuals with autosomal recessive diseases [4, 6, 9].
Homozygous disease-causing mutations could be detected
in single cases of outbred populations within homozygous
areas often larger than 2 Mb in size [4]. Another study
explored the potential of estimating individual autozygos-
ity from data on runs of homozygosity (ROHs) in different
European populations and showed that ROHs measuring up
to 4 Mb are common in outbred populations [17].
In six of our CMT patients mutations in the SH3TC2
gene were identified including a novel alteration which
may be traced back to a common founder. As described
previously [18], CMT4C is one of the most common
genetic ARCMT subtypes followed by CMT4A caused by
mutations in GDAP1 [19] which were found in three of our
patients.
Of special interest is the homozygous c.250G [ C
(p.G84R) mutation (Fig. 1b) in the small heat shock pro-
tein 27 gene (HSPB1) in patient G2-7. HSPB1 has origi-
nally been associated with autosomal dominant HMSN
(CMT2F/CMT2L) and dHMN [20], but a recent study
demonstrated that distinct HSPB1 mutations may also act
in a recessive way to cause dHMN [13]. The same study
also reported four novel heterozygous mutations in HSPB1
including the c.250G [ C (p.G84R) mutation in a patient
with a dHMN phenotype. The patient included in our study
did not report any neuromuscular problems in his sibs,
parents or grandparents except for considerable foot
deformity in the paternal grandfather. However, subsequent
examination of the patient’s parents heterozygous for this
HSPB1 mutation detected a subclinical phenotype. As
shown for other genes involved in the pathogenesis of
CMT, like GDAP1, NEFL, MFN2, PMP22, EGR2, and
HSPB1 mutations should also be considered in both AD-
CMT and ARCMT patients [21–28].
In summary, this study identified a novel, presumably
founder mutation in SH3TC2, a novel homozygous muta-
tion in MFN2, and the rare event of severe CMT caused by
a homozygous HSPB1 mutation. We suggest that SNP
array-based homozygosity plotting without linkage analy-
ses is a simple, practical, and inexpensive screening
method that should be initially applied to ARCMT patients
with known parental consanguinity and can also be used
for a small and selected number of patients with sporadic
CMT syndrome.
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Fig. 3 Homozygosity profiles. Homozygosity profiles of selected
individuals. The intervals of homozygosity are shown as (blue blocks)
and are plotted across the genome for each individual. The
chromosomal positions of the homozygous intervals are indicated
on the x-axis, the length of each block represents the size of the
homozygous interval in basepairs (bp). The y-axis shows the number
of homozygous SNPs (hSNPs). The physical positions of the known
ARCMT genes are included and shown in green color. a High-density
(250 K Nsp) array-derived homozygosity profiles of G1-2 and a
distantly related cousin (G1-2-dc) (MFN2 marked in red) compared to
a control individual with no parental consanguinity. b Low-density
(10 K 2.0) array-derived homozygosity profiles for probands G1-5,
carrying distinct GDAP1 mutations each (marked in red) and for a
control sample
b
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